Fulgent Genetics, Inc.
$493.16M- Market cap
- $542.88M
- Debt
- +$476.00K
- Cash
- −$50.19M
Capital structure 100% equity / 0% debt · EV / Revenue 1.53x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: FLGT stock price at premium vs MET $19.73 current versus $9.44 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MET's multiple
Implied fair value · at FLGT's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: FLGT FY 2025 (ended Dec 31, 2025) · MET FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 100% equity / 0% debt · EV / Revenue 1.53x
Capital structure 81% equity / 19% debt · EV / Revenue 0.66x · EV / EBITDA 8.71x
MET carries the larger enterprise value at $51.22B against $493.16M; MET trades on the lower EV / Revenue multiple (0.66x vs 1.53x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
FULGENT GENETICS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
MetLife, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.00x
0.52x
Net debt / EBITDA
Leverage against operating earnings
1.15x
-1.84x
Cash and equivalents
Liquid reserves on the balance sheet
$50.19M
$25.63B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NEOGENOMICS INC
FLGT vs NEO
Natera, Inc.
FLGT vs NTRA
Guardant Health, Inc.
FLGT vs GH
EXACT SCIENCES CORP
FLGT vs EXAS
OPKO HEALTH, INC.
FLGT vs OPK
AFLAC INC
FLGT vs AFL
American International Group, Inc.
FLGT vs AIG
LINCOLN NATIONAL CORP
FLGT vs LNC
HARTFORD FINANCIAL SERVICES GROUP, INC.
FLGT vs HIG
$476.00K
$14.82B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.